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Point-by-point response to the Reviewers 
 
Reviewer#1: 
 
The manuscript “Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by 
selenium in 3xTg-AD mice” by Van der Jeugd et al contains the evaluation of the effects of a 4-months 
chronic dietary sodium selenate supplementation in female 3xTg-AD mice at 12-14 months of age on 
behavioral and biochemical test. Despite that the work is appropriated planned, performed, discussed 
and concluded there are a variety of minor but important issues that need further detail explanation:  
 
1. The title. Consider the replacement of Reversal for a more appropriate term. The fact that treatment is 
performed on time-dependent lesion the observation seems to obey to a halting effect (impeding 
efficiency of progression).  
 
Response:  
We thank the Reviewer for her/his valuable comments. 
 
We agree that selenium treatment was extended for 4 months (from 8 to 12-14 months of age) during the 
progression of the pathological and behavioral symptoms in 3xTg-AD mice.  However, since the 
cognitive and neuropsychiatric symptoms start already as early at 4-6 months of age in this AD mouse 
model (Oddo et al., 2003; Billings et al., 2005; Gimenez-Llort et al., 2007; España et al., 2010), the results 
obtained at advanced disease stages (12-14 months) are unlikely to be considered a 'impeding efficiency 
of progression' . Therefore, we consider that ¨Reversal¨ is a more appropriate term in this case. 
 
 
2. The model: The choice of the AD model (3x-Tg and sex) considered is well justified. However, the 
used of its old population lacks sufficient rational. In theory the window of age selected is the most 
difficult to revert, and its comparison with a younger group should have been performed.  
 
Response:  
 
Previous studies have shown beneficial effects of Se-Met treatment in 4 month-old 3xTg-AD mice (Song 
et al., 2014; Zhang et al., 2016), so we decided to focus on advanced disease stages were 
neuropathological changes were already present in the brain of 3xTg-AD mice.  We selected the age of 8 
months for the treatment because the neuropathological hallmarks of disease are clearly present at this 
age (see comment below). Indeed, the amelioration of pathological and behavior symptoms at this old 
age is a therapeutic challenge, but it was succesfuly achieved. The proposal of a comparison study with a 
younger group (e.g 3-4 months) is very interesting, but besides spanning the study to target to prodromal 
or premorbid stages, it has  been previously performed by others.  
 
 
3. The supplement. How does the sodium selenate concentration compared with previous studies?. 
Please include also the brand (composition) of pellets used for feeding, since selenate content may vary. 
Se levels in plasma and/or brain should be provided as indication of incorporation or deficiency 
correction.  
 
Response:  
 
We have now described (first paragraph, Materials and methods, page 13) the brand of the food pellets 
that contain 0.3 mg selenium/kg (ssniff® R/M-H).  
 
Several studies have evaluated diet supplementation of selenium derivates in AD mouse models. We 
performed chronic supplementation of sodium selenate (12 µg/ml) in drinking water ad libitum. This 
concentration is similar to those used in  previous studies in AD mouse models (see Table below). 
Notably,  a chronic treatment with Se-Met (6 µg/ml) in drinking water for 3 months showed significant 
elevated levels of selenium in the cortex and hippocampus (1.2-1.5 mg/kg) indicating incorporation of Se 
in the brain (Song et al., 2014).  
Based on these previous studies, we have added a comment on this issue in the Materials and methods 
section (page 13). 
 
 
 
Table. Summary of preclinical studies using Se compounds in AD mouse models 
 
4. Revise the sentence “The chemical structure of selenomethionine, which contains methionine and 
selenium, may result in different and/or additional therapeutic properties” included at the discussion. A 
brief note specifying the differences between inorganic and organic Se pools and their metabolic fate is 
recommended.  
 
Response:  
As suggested  by the Reviewer we have changed the above sentence for the following one (Discussion 
section, second paragrap of  page 10): 
 
Differences in the inorganic (sodium selenate) and organic (selenomethionine) source and metabolic fate 
of the distinct Se compounds may result in different and/or additional therapeutic properties. 
 
 
5. Figure 4B should be checked for mw markers. Tau band patterns obtained with the different 
antibodies are difficult to compare. Previous studies supported that vanadate impeded tau 
phosphorylation. Can selenate interfere in such reaction as well?.  
 
Response:  
As suggested  by the Reviewer we have corrected the position of the molecular weight markers in the tau 
blots (Figure 4B) according to the original gels shown in the Supplemental Information. Figure 4 has 
been re-edited. 
  
A number of studies have shown that Tyr phosphatase inhibitors ((per)vanadate and orthovanadate) 
increase phosphorylation of tau at Tyr residues (e.g. Tyr 394) (Derkinderen et al., 2005), and pervanadate 
induces tau dephosphorylation in living cells (Mandell and Banker, 1996). In the latter study, it is 
Se	treatment	in	AD	mouse	models
Supplementation Dose Treatment Age Model Sex Behavior Reference
Se-Met 6	μg/ml Drinking	water	for	3	months8	months 3xTg-AD males/females Improvement	spatial	learning/memory	MWM Zhang	Z-H	et	al.,	J	Neuroci	2017
Se-Met 6	μg/ml Drinking	water	for	3	months4	months 3xTg-AD males/females Improvement	spatial	learning	MWM Song	et	al	J	Alz	Dis	41	(2014)
Se-Met 6	μg/ml Drinking	water	for	3	months4	months 3xTg-AD males/females Improvement	spatial	learning	MWM Zhang	Z-H	et	al.,Int	J	Mol	Sciences	2016
Se-Met 6	μg/ml Drinking	water	for	3	months4	months 3xTg-AD males/females Improvement	spatial	learning	MWM Zheng	R.et	al.,	BBRC		2017
Se-Met 6	μg/ml Drinking	water	for	3	months8	months 3xTg-AD males/females Improvement	spatial	learning	MWM Zhang	ZH	et	al	Matallomics	8	(20169
Sodium	selenate 1.2	mg/ml Drinking	water	for	3	months5	months	 TAU441 ? thigmotactic	behavior Corcoran	et	al	J	Clin	Neurosci	17	(2010)
Improvement	spatial	learning	MWM
Sodium	selenate 12	μg/ml Drinking	water	for	5	weeks 6	Weeks K3	K369I Improve	motor	performance	(rota-rod) Van	Eersel	et	al	PNAS	107	(2010)
12	μg/ml Drinking	water	for	4	months4	months K3	K369I
12	μg/ml Drinking	water	for	4	months8	months pR5	Tau	P301L	tg Improvement	of	contextual	memory
Sodium	selenate 12	μg/ml Drinking	water	for	4	months8	months 3xTg-AD females Reversal	spatial	learning/memory	MWM Van	der	Jeugd	et	al.		(this	study)
Reversal	of	contextual	memory	deficits
Ameliorates	anxiety	,	social	and	nesting	behavior
suggested that pervanadate decreases pTau levels indirectly by affecting ¨likely¨ Tyr phosphorylation of 
Cdk5 and/or GSK3β. Although we can not discard a link between vanadate and selenate, since vanadate 
affects mainly tau phosphorylation at Tyr residues it is unlike that vanadate interfere with the selenate-
mediated tau Ser dephosphorylation/aggregation observed in our study. 
 
 
6. Brain regions. How does the regional variation obtained relate with the described tau pathology 
evolution?. This fact should be commented in the reversal/retardation scenario.  
 
Response:  
 
Tau pathology in the 3xTg-AD mice starts in the basolateral amygdala by 4 months of age and extends to 
the hippocampus and cortex by 6 months (Oddo et al., 2003; España et al., 2010). We detected a 
significant decreased of pTau by Se treatment in hippocampal lysates and aggregated tau (MC1)-positive 
neurons in CA1 region  (Veh, 45.9 ± 3.3 vs Se, 26 ± 6.6) and temporal auditory cortex (Veh, 3.1 ± 1 vs 
Se, 0.9 ± 6.3; Table 1), whereas MC1-positive neurons are not significantly reduced in other hippocampal 
and cortical regions.  
 
We have added a brief description of spatial tau pathology progression in 3xTg-AD mice and its relation 
to amelioration by Se treatment in the Discussion section (last paragraph page 9 and first paragraph Page 
10) as follows: 
In 3xTg-AD mice, tau pathology begins in the basolateral amygdala and then extends to the 
hippocampus and cortex, whereas hippocampal synaptic transmission and plasticity deficits are evident at 
6 months of age or even earlier (Oddo et al., 2003; España et al., 2010; Clark et al., 2015). Besides that 
treatment was extended during the progression of pathological and behavioral features (i.e., from 8 to 12-
14 months of age), Se reduced aggregated tau-positive neurons in CA1 hippocampus and temporal 
auditory cortex in 3xTg-AD mice. 
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Abstract 
 
 
Accumulation of amyloid-β plaques and tau contribute to the pathogenesis of Alzheimer’s disease 
(AD), but it is unclear whether targeting tau pathology by antioxidants independently of amyloid-β 
causes beneficial effects on memory and neuropsychiatric symptoms. Selenium, an essential 
antioxidant element reduced in the aging brain, prevents development of neuropathology in AD 
transgenic mice at early disease stages. The therapeutic potential of selenium for ameliorating or 
reversing neuropsychiatric and cognitive behavioral symptoms at late AD stages is largely unknown. 
Here, we evaluated the effects of chronic dietary sodium selenate supplementation for 4 months in 
female 3xTg-AD mice at 12-14 months of age. Chronic sodium selenate treatment efficiently 
reversed hippocampal-dependent learning and memory impairments, and behavior- and 
neuropsychiatric-like symptoms in old female 3xTg-AD mice. Selenium significantly decreased 
aggregated tau-positive neurons and astrocytosis, without globally affecting amyloid plaques, in the 
hippocampus of 3xTg-AD mice. These results indicate that selenium treatment reverses AD-like 
memory and neuropsychiatric symptoms by a mechanism involving reduction of aggregated tau 
and/or reactive astrocytes but not amyloid pathology. These results suggest that sodium selenate 
could be part of a combined therapeutic approach for the treatment of memory and neuropsychiatric 
symptoms in advanced AD stages. 
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Introduction 
 
Alzheimer’s disease (AD) is characterized by progressive memory decline and emotional and 
neuropsychiatric symptoms associated with accumulation of amyloid-β (Aβ) plaques and tau-
containing neurofibrillary tangles (NFTs) 1. Cognitive decline correlates better with progression of 
tau pathology in the hippocampus rather than amyloid plaques in neocortical regions 2. These 
classical pathological hallmarks accumulate similarly in the hippocampus and cortex of transgenic 
3xTg-AD mice, which develop age-dependent hippocampal-dependent cognitive deficits and 
neuropsychiatric-like disturbances 3-6. Targeting Aβ and phosphorylated tau ameliorate and/or 
reverse memory and synaptic deficits in 3xTg-AD mice 7, although it is still unclear whether 
targeting tau independently of Aβ may have therapeutic benefits on cognition and/or emotional 
symptoms at late AD stages.  
Epidemiological studies show imbalance of essential inorganic elements, including selenium 
(Se), in the brain during aging and AD 8,9. Plasma levels of Se decline during aging, mild cognitive 
impairment and AD, and its deficiency is associated with increased risk of developing AD 10,11. Se 
regulates critical cellular antioxidant signaling pathways by acting as Se-containing compounds or 
selenoproteins being beneficial against neurotoxicity and oxidative damage in AD 12. A number of 
clinical trials demonstrated preventive or therapeutic effects of Se alone or combinated with 
antioxidants in multiple human diseases 13. Randomized clinical trials with Se plus antioxidants are 
currently in progress in AD but without not reported outcome data 14,15.  
Sodium selenite and selenate protect hippocampal neurons against Aβ42 toxicity and reduce amyloid 
burden in APP/PS1 transgenic mice 16-18. Chronic sodium selenate in drinking water mitigates tau 
pathology in AD and traumatic brain injury murine models 19,20. Sodium selenate-treated tau 
transgenic mice exhibit improved spatial learning and memory and show lower levels of 
phosphorylated and insoluble tau levels in the hippocampus and amygdala 21,22. More recently, 
selenomethionine, supplemented before appearance of pathology, was shown to prevent spatial 
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learning deficits, and reduced total and phosphorylated tau levels by promoting autophagy in mix sex 
groups of young 3xTg-AD mice 20,23. Whether Se supplemented as a natural salt reverses emotional 
and memory symptoms specifically in AD female mice at late stages remain unclear. In this study, 
we investigated the effects of chronic dietary sodium selenate supplementation on both cognitive and 
neuropsychiatric-like domains, and studied the pathological mechanisms involved, in old 3xTg-AD 
mice. 
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Results 
 
Chronic sodium selenate treatment stabilizes idiopathic behaviors in 3xTg-AD mice 
 
3xTg-AD mice show age- and sex-related differences in brain AD-like pathology and oxidative 
stress and behavior, which include enhanced amyloid pathology in females 24,25, and immunological 
and behaviors changes in males 26-28. To evaluate specifically the effects of Se in females, the sex 
more affected by the disease in human, we evaluated the effects of 4 months-chronic Se 
supplementation diet in 12-14 month-old female control (WT) and 3xTg-AD mice, which started 
treatment at 8 months of age. No significant differences were found in rotarod test between genotype 
and treatment groups [F (3,44) = 0.512, P > 0.05; data not shown]. During ethological assessment, 
we found no significant differences among groups for rearing seated or against the wall, nor regular 
or intense grooming and chewing. By contrast, we found significant differences between groups in 
locomotion [F (3,44)=5.427, P = 0.002], free rearings [F (3,44)=3.313, P = 0.029], sifting [F 
(3,44)=5.011, P = 0.005] and stillness [F (3,44)=6.425, P = 0.001] (one-way ANOVA; Figure 1A). 
Bonferroni test revealed that 3xTg-AD mice showed reduced locomotion (t=3.926, P = 0.002), free 
rearings (t=3.103, P = 0.021) and sifting (t=3.472, P = 0.007), whereas Se significantly reversed 
these alterations in locomotion (t=3.451, P = 0.008), sifting (t=7.24, P = 0.001) and stillness 
(t=4.197, P < 0.001). Corner index measures revealed no group differences on corner visits [F 
(3,44)=2.056, P > 0.05] but significant rearings differences among groups [F (3,44)=49.546, P < 
0.001] (Figure 1B). 3xTg-AD mice visited slightly fewer corners and performed less rearings 
compared to WT mice (P < 0.001), a phenotype that was significantly ameliorated by Se treatment 
(rearings: t=4.276, P = 0.001) (Figure 1B).  
When testing anxiety in the dark/light test, 3xTg-AD mice took much longer than all other groups to 
emerge from the dark compartment [group effect, latency: F (3,44)= 7.199, P < 0.001; transitions: F 
(3,44)=12.29, P <0.001]. Post-hoc comparisons revealed differences between vehicle-treated 3xTg-
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AD and all other groups (all P < 0.001), whereas sodium selenate significantly reduced latencies 
(t=3.021, P = 0.26) and increased transitions (t=5.724, P = 0.001) in 3xTg-AD mice (Figures 1C,D). 
In the single-trial passive avoidance test, latencies to enter the dark compartment were not different 
among groups during the training day (P > 0.05). However, significant latencies differences were 
evident between groups during testing at 24 h [F (3,44)=3.058, P = 0.04], whereas latencies were 
significantly rescued by Se treatment in 3xTg-AD mice (t=2.587, P = 0.0172; Figure 1E). When 
assessing well-being and social collaboration in the nest building test, 3xTg-AD mice showed less 
nest-building ability than WT groups, whereas Se treatment significantly increased nesting activity in 
3xTg-AD mice [F (3,10)=35.17, P < 0.001; Figure 1F,G]. 
 
Rescue of hippocampus-dependent spatial learning and memory in 3xTg-AD mice by sodium 
selenate treatment 
 
In the Morris water maze (MWM), a spatial memory task that depends on the hippocampus, all 
experimental groups improved significantly during the training days but with significant learning 
differences between the groups [Two-way RM ANOVA; Escape latencies: group effect, F (3,40) = 
7.74, P < 0.001; day effect, F (4,160) = 43.514, P < 0.001; Pathlengths: group effect, F (3,40) = 
15.66, P < 0.001; day effect: F (4,160) = 33.5752, P < 0.001; Figure 2A]. Post hoc comparisons 
revealed that untreated 3xTg-AD mice displayed longer escape latencies in comparison to other 
groups at days 3 to 5 (all P < 0.001). Swimming velocities were not different between the groups [F 
(3,40) =2.305, P > 0.05], but all mice became faster and better swimmers during the days (F (4,160) 
=3.887, P < 0.01). In the probe trial, both WT groups displayed a clear preference searching in the 
target quadrant (WT Veh: 39% time; WT Se: 36%) compared with 3xTg-AD mice (22%) (Figures 
2B,C). After Se treatment, 3xTg-AD mice spent significantly more time in the target quadrant (39%) 
indicating rescue of reference memory [F (3,43) = 5.121, P = 0.004]. Indeed, heat plots reveals that 
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control groups and Se-treated 3xTg-AD mice mostly searched close to the designated platform 
position, whereas vehicle 3xTg-AD mice seemed to be circling more aimlessly (Figure 2C). 
During acquisition training, different spatial search strategies can be used (Figure 2D). When 
counting the number of trials categorized in three main search strategies, we observed that both 
vehicle and Se-supplemented WT mice increasingly applied spatial strategies to locate the hidden 
platform (Figure 2D). On day 5, vehicle- and Se-supplemented WT mice almost exclusive used 
hippocampal-dependent spatial strategies (72% and 65%, respectively), compared to vehicle 3xTg-
AD mice (17%), which tended to use scanning and random strategies (36%). Notably, the use of 
spatial strategies increased after Se treatment in 3xTg-AD mice (69%).  
 
Sodium selenate does not affect accumulation of amyloid plaques nor intraneuronal Aβ 
 
To determine whether Se could be beneficial in cognition by affecting AD-related pathological 
hallmarks, we next performed Aβ histological analyses. 3xTg-AD mice accumulate abundant 
intracellular Aβ and amyloid plaques in the hippocampus, especially in the subiculum, and only 
sporadically in the neocortex both in vehicle- and Se-treated conditions (Figure 3A). Quantitative 
analysis revealed no significant differences in the number of dense, sparse or total amyloid plaques 
in the hippocampus between vehicle- and Se-treated 3xTg-AD mice (P > 0.05; Figures 3B). Since 
intraneuronal Aβ is one of the earliest neuropathological hallmarks of 3xTg-AD mice that coincides 
with memory deficits 4, we next quantified Aβ-containing neurons in the hippocampus. Quantitative 
analyses showed no significant changes in the number of Aβ-positive CA1 pyramidal neurons 
between vehicle- and Se-treated 3xTg-AD mice (P > 0.05; Figures 3A,B). 
 
Sodium selenate reduces accumulation of aggregated tau in 3xTg-AD mice 
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3xTg-AD mice develop age-dependent tau pathology starting in the basolateral amygdala at 6-9 
months and cortex and hippocampus at 12 months of age 3,6. Staining of 3xTg-AD brains with anti-
phosphorylated (CP13, PHF1) and conformational (MC1) tau antibodies show abundant tau 
accumulation in soma and axons of neurons in the hippocampus (CA1, CA2, CA3, DG), amygdala 
and cortex (parietal, auditory and entorrhinal cortices) (Figure 4A). Quantitative analyses revealed 
no major changes in the number of phosphorylated tau-positive neurons in all regions analyzed in 
3xTg-AD mice after Se treatment (P > 0.05; Figure 4A, Table 1). The number of MC1-positive 
neurons was, however, significantly reduced in CA1 hippocampus and auditory cortex in 3xTg-AD 
mice after Se treatment (P < 0.05; Figure 4A, Table 1). Western blot analysis showed a significant 
increase of total (TG5 and 17025 antibodies) and phosphorylated tau at Ser202 (CP13), Thr231 
(AT180), Ser396/404 (PHF1) residues in hippocampal lysates of vehicle-treated 3xTg-AD mice 
compared with WT groups (P < 0.05; Figure 4B). In 3xTg-AD mice, Se treatment slightly decrease 
phosphorylated tau levels but it significantly reduced total tau, as analyzed with two distinct 
antibodies (TG5 and 17025) (P < 0.05; Figures 4B,C). Surprisingly, biochemical analysis showed a 
significant increase of phosphorylated (Ser9)/total GSK3β ratio in the 3xTg-AD groups (P < 0.001), 
which inversely reflects its enzymatic activity (Figure 4B,C). Finally, GFAP staining revealed that 
3xTg-AD treated with Se show a global significant reduction of GFAP staining in CA1, CA3 and 
DG regions (P < 0.05) but not in corpus callosum (Figure 5A). Biochemical analysis confirmed a 
significant increase of GFAP protein levels in hippocampal lysates of 3xTg-AD mice, which were 
reduced after Se treatment (P < 0.001; Figure 5B). Together, these results indicate that chronic 
sodium selenate treatment reduces accumulation of aggregated tau and astrocytosis without globally 
affecting phosphorylated tau in the hippocampus of 3xTg-AD mice. 
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Discussion  
There is growing evidence that besides genetic and non-genetic risk factors dementia is 
influenced by a number of environmental factors. A recent review of sixty studies reveals only a 
limited number of environmental risk factors for dementia, including selenium 9, an inorganic 
element whose deficiency is associated with increased risk of developing AD 10,29,30 (see 11 for 
review). Importantly, our study shows that chronic treatment with sodium selenate, a common 
natural source of Se, efficiently reverses neuropsychiatric and cognitive symptoms in old 3xTg-AD 
female mice with advanced amyloid and tau pathologies. Importantly, memory improvement is 
associated with reduced total/aggregated tau and astrocytosis but unchanged Aβ pathology in the 
hippocampus. These results suggest for the first time that reducing pathological tau with Se may be 
useful for the treatment of memory and neuropsychiatric symptoms in AD.  
Our results indicate that chronic Se treatment efficiently ameliorates neuropsychiatric-like 
symptoms of dementia, whose effects contribute significantly to the clinical profile in mild cognitive 
impairment and AD 31,32. As previously reported 5, 3xTg-AD mice display less exploratory behavior, 
as revealed by reduced locomotor activity, free rearings, sifting behaviors and visiting fewer corners 
and increased stillness. This behavioral phenotype could reflect a subtle change in idiopathic 
behaviors, since walling, grooming and chewing are not altered. Interestingly, Se treatment has 
positive effects on fine motoric properties, and anxiety as evaluated by corner visit behaviors, and 
does not affect gross motor functions nor working memory. In addition, Se improves nest building, 
an ethological behavior involving high executive function, and therefore useful to assess progressive 
loss of executive function seen in AD 33. Besides, nesting behavior is sensitive to apathy and 
neophobia 34, two common neuropsychiatric symptoms in individuals with AD 31,35. Se also reduces 
neophobic, anxiety and fear-related behaviors in 3xTg-AD mice, a result consistent with increased 
locomotor and rearing activities. This result is relevant since emotional symptoms, including anxiety 
and fear, are early clinical features of mild cognitive impairment and AD 36, although cellular 
mechanisms involved are unknown. Importantly, accumulation of intraneuronal Aβ and 
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phosphorylated tau in the basolateral amygdala seems to contribute to these symptoms 6, whereas Se 
treatment causes a slight reduction in tau pathology in this region in 3xTg-AD mice (Table 1). While 
tau pathology in the amygdala could be involved in the emotional disturbances observed in AD, 
understanding the molecular mechanisms by which Se ameliorates AD-like neuropsychiatric 
symptoms will be relevant to treat the psychiatric and behavioral symptoms of dementia. 
AD mouse models develop memory deficits associated with disrupted synaptic function in the 
hippocampus. We observed impaired spatial learning and memory in old 3xTg-AD mice likely due 
to use of less directed search navigation strategies 4,6,37. This is in concordance with studies showing 
that hippocampus-impaired animals use spatial search strategies less frequently than controls 38-40. Se 
treatment increases the use of direct spatial strategies (e.g., direct swimming, focal search…) 
resulting likely in memory improvement in 3xTg-AD mice. Indeed, sodium selenate and 
selenomethionine increase spatial learning in the water maze in young AD transgenic mice 20,22,41, 
and a multi-nutrient diet containing Se alleviates cognitive deficits in APP/PS1 mice by increasing 
the use of navigation search strategies 39. This effect was mediated by reduction of Aβ and amyloid 
plaques in young APP/PS1 mice, while it was independent of brain amyloid pathology in old mice 
39,42. Importantly, our results indicate that sodium selenate does not affect the number of amyloid 
plaques nor intracellular Aβ-containing neurons in old 3xTg-AD mice. Differences in the inorganic 
(e.g. sodium selenate) and organic (e.g. selenomethionine) source and metabolic fate of the distinct 
Se compounds may result in different and/or additional therapeutic properties. Nonetheless, 
hippocampal-dependent memory recovery by Se is reinforced by rescue of associative memory in the 
passive avoidance task, a similar result than that found in tau transgenic mice 21. Although the 
pathological mechanisms underlying Se-mediated hippocampal-dependent memory recovery are still 
unclear, the fact that Se reduces total and aggregated tau in the hippocampus strongly suggests a tau-
mediated mechanism. In 3xTg-AD mice, tau pathology begins in the basolateral amygdala and then 
extends to the hippocampus and cortex, whereas hippocampal synaptic transmission and plasticity 
deficits are evident at 6 months of age or even earlier 3,6,43. Besides that treatment was extended 
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during the progression of pathological and behavioral features (i.e., from 8 to 12-14 months of age), 
Se reduced aggregated tau-positive neurons in CA1 hippocampus and temporal auditory cortex in 
3xTg-AD mice. Notably, decreasing endogenous tau or reducing tau pathology independently of Aβ 
ameliorate memory deficits in AD mice 44,45. By contrast, phosphorylated tau was not globally 
affected by Se treatment, a result in accordance with unchanged inactive phosphorylated GSK3β 
levels. Recent investigations show, however, that Se mitigates tau hyperphosphorylation and 
aggregation by modulating Akt/GSK3β and/or PP2A activities and autophagy pathways 20-23. Our 
results reinforce the view that tau pathology contributes to AD-like neuropsychiatric and memory 
deficits, and that reducing aggregated tau without affecting amyloid pathology is beneficial in 3xTg-
AD mice. 
The exact mechanism(s) mediating functional recovery of memory neural circuits by Se is 
unclear. Age-dependent mitochondrial dysfunction and reduced metal homeostasis and antioxidant 
defense directly affect synaptic function leading to memory loss, whereas synaptic failure is an early 
pathological feature that plays an important role in cognitive impairment in AD 46,47,48. Whether 
sodium selenate reverts hippocampal-dependent memory deficits by affecting synaptic function 
remains unclear. One possibility is that seleno-derivatives, acting as antioxidants may affect synaptic 
transmission and/or plasticity 49. Indeed, 3xTg-AD mice develop neuronal oxidative stress caused by 
reduced glutathione and increased reactive oxygen species 50, whereas selenomethionine increases 
glutathione levels in these mice 20. Moreover, disrupted oxidative stress and energy metabolism 
affect the production and accumulation of Aβ and tau pathologies, which can exacerbate 
mitochondrial and synapse dysfunction 46. It is tentative to speculate that Se improves synaptic 
function leading to memory and psychiatric recovery by reducing directly or indirectly oxidant and 
tau toxic species. Since tau is involved in synaptic pathology in AD 51, the synaptic mechanisms 
regulated by Se may be important for future therapeutic strategies 
In summary, chronic Se supplementation efficiently ameliorates neuropsychiatric-like and 
memory symptoms and reduces tau aggregation at advanced AD pathological stages. Considering 
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that Se and antioxidant compounds progressively decrease in brain and plasma in mild cognitive 
impairment and AD patients 52-54, our results may have important diagnostic and clinical 
implications. In this context, a signature of at least six essential inorganic elements in serum that 
includes Se was proposed recently to monitor AD progression 55. Furthermore, a sodium selenate diet 
is safe, tolerated and improves neuroimaging measures in mild-moderate AD patients 14. Nutritional 
supplementation with Se may represent a promising therapeutic strategy to ameliorate and/or reverse 
neuropsychiatric and cognitive symptoms in dementia. 
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 Materials and Methods 
 
Experimental design and transgenic mice  
Triple-transgenic AD mice (3xTg-AD; C57BL/6 x 129 background) harboring the human 
PS1 (M146V), APPSwe (K670N/M671L) and tau (P301L) transgenes and wild-type (WT) mice3, 
were bred at the Universitat Autònoma de Barcelona (UAB). All mice were females (3xTg-AD=24 
and WT=21) housed in groups of 3-6 per cage in standard laboratory conditions, including a 12 h 
light/dark cycle and ad libitum access to water and food pellets (Brand: ssniff® R/M-H, containing 
0.3 mg Se/Kg; ssniff Spezialdiäten GmbH, Germany). We treated 8 month-old mice with vehicle 
(3xTg-AD, n=9; WT, n=11) or 12 μg/ml sodium selenate (Se; Sigma-Aldrich/Merck, Darmstadt, 
Germany) (3xTg-AD, n=15, one died during testing; WT, n=10) added to the drinking water ad 
libitum, and continued throughout behavioral testing.  Chronic treatment with Se-Met (6 µg/ml) in 
drinking water was shown previously to elevate Se in the cortex and hippocampus (1.2-1.5 mg/kg) 
indicating incorporation of Se in the brain 20. The mice were approximately 12 months old at 
behavioral testing, and 13-14 months old at physiological, biochemical and pathological analyses.  
  
Behavioral experiments 
Behavioral testing successively included the following tests (in this order): rotarod, ethogram, 
nesting behavior, corner index, dark/light box, Morris water maze and passive avoidance. Motor 
coordination and equilibrium were tested on an accelerating rotarod (MED Associates Inc., St. 
Albans, Vermont, USA). Mice were first trained on a constant speed (4 rpm, 2 min), before starting 
with four test trials (inter-trial interval, 10 min). During these trials, mice had to balance on the 
rotating rod that accelerated from 4 to 40 rpm within 5 min. The latency until the mice fell from the 
rotating rod was recorded, up to a maximum of 5 min 56,57. Ethological assessments were carried out 
using a rapid time-sampling behavioral checklist technique, as described previously 58. Each mouse 
was observed individually for 5 s periods at 1min intervals over 15 consecutive min, using an 
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ethologically based behavioral checklist (occurring alone or in any combination) that included: 
sniffing, locomotion, rearing seated, rearing to wall, rearing free, sifting, grooming, intense 
grooming, chewing and stillness. This cycle of assessment was repeated twice over an initial 
exploratory period of 60 min, total counts for each behavior were analysed. Nesting behavior was 
evaluated by introducing a piece of paper tissue inside the home cage. The presence and quality of 
the nest were rated two days later on a 1 to 5 point scale 34: 1 not noticeably touched, 2 partially torn 
up, 3 mostly shredded but often no identifiable site, 4 identifiable but flat, 5 perfect or nearly. 
Pictures were taken prior to evaluation for documentation. Two experimenters scored the nest blind 
and independently of each other. Neophobia was measured using the corner index recorded in 
standard transparent home-cages. In a 30s period, the number of visited corners, as well as the 
rearings in the corners were counted as described 5. Anxiety behavior was examined in the dark/light 
box (0,50 m × 0,50 m) divided into same size dark and light sides. The mouse was placed in the dark 
side of the box for 10 sec acclimatization. A door separating the two compartments was opened and 
the amount of time that the mouse took to emerge fully (all four paws) into the open area, total time 
in the light area, and number of transitions were measured for 5 min. Hippocampus-dependent spatial 
memory abilities were examined in the hidden-platform version of the water maze as described 59. 
Time required to locate the hidden platform (escape latency), distance traveled (path length), and 
swimming speed were recorded using the Ethovision video tracking system (Noldus Information 
Technology, Wageningen, The Netherlands) as described 56,60. Swim paths for each mouse in each 
trial were plotted and categorized into eight mutually exclusive categories: thigmotaxis, chaining, 
random search, scanning, directed search, focal incorrect, focal search and direct swimming to the 
platform, of which the latter three are considered true spatial strategies. Two days following the 
acquisition phase, a 100 sec probe trial, in which the platform was removed, was performed. We 
visualized swimming paths using a custom-made MATLAB protocol. Single-trial passive avoidance 
learning was examined in a grid-floor apparatus (MED Associates Inc., St. Albans, Vermont, USA) 
as described 40,60.  Briefly, mice were dark adapted for 30 min, and then placed in the small 
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illuminated compartment. The sliding door to the dark compartment was opened after 5 sec, and the 
entry latency was recorded. When mice entered the dark compartment a foot shock (0.3 mA, 1 sec) 
was delivered. Retention was tested 24 h later without delivering the shock.   
 
Biochemical analysis 
For biochemical analysis, half hippocampi were lysed in cold-lysis buffer (62.5 mM Tris 
hydrochloride, pH 6.8, 10 % glycerol, 5 % β-mercaptoethanol, 2.3 % sodium dodecyl sulfate [SDS], 
5 mM NaF, 100 µM Na3VO4, 1 mM EDTA, 1mM EGTA) containing protease and phosphatase 
inhibitors (Roche España, Barcelona, Spain) and boiled at 100°C 61. Protein content was quantified 
with the Coomassie (Bradford) protein assay kit (Thermo Fisher Scientific, USA), resolved on SDS-
polyacrylamide gel electrophoresis and detected by Western blotting using the following antibodies: 
rabbit anti-tau (Tau17025; 1:5000), mouse anti-phosphorylated Thr231 (AT180; 1:200), Ser202 
(CP13; 1:250), and Ser396/404 (PHF-1; 1:250), abnormal tau conformation (aa 5-15 and 312-322; 
MC1), total tau TG5 (Tau 220-242; 1:500), and phosphorylated Ser9 GSK3β  (1:1000; Cell 
Signaling, Danvers, Massachusetts) and anti-GSK3β (1:2500; BD Biosciences, San Jose, CA, USA), 
GFAP (1:250; Agilent, Santa Clara, CA, USA) and GAPDH (1:100000; Thermo Fisher Scientific). 
Bands were detected with enhanced chemiluminescent reagent in a ChemiDoc MP System (Bio-Rad) 
and quantified in a linear range using the ImageLab 5.2.1 software. Original blot images are shown 
in Supplementary Information. 
 
Immunohistochemical analysis 
For immunohistochemical analysis, vehicle- and Se-treated WT and 3xTg-AD mice (n=6-7/group) 
were perfused with PBS followed by 4% paraformaldehyde. Left brain hemispheres were dehydrated 
in ethanol before paraffin embedding. Coronal brain sections (5 μm) were deparaffinized in xylene, 
rehydrated and incubated with 3% hydrogen peroxide in methanol. For Aβ staining, sections were 
treated with 60% formic acid (6 min), a protocol that allows specific labeling of Aβ over full-length 
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APP in APP transgenic mice as described 6. For tau and GFAP staining, sections were pretreated 
with citrate buffer and microwave heated (10 min) to allow antigen retrieval. Sections were washed 
in TBS, incubated overnight with antibodies against human Aβ1-16 (6E10; 1:1,000; Covance), 
hyperphosphorylated tau (PHF1, 1:50; CP13, 1:50), conformational aggregated tau (MC1, 1:20) or 
GFAP (1:200), and processed for avidin-biotin immunoperoxidase staining using the Vectastain Elite 
ABC kit (Vector Laboratories, Burlingame, CA) 6. Sections corresponding to bregma -2, -2.5, -3, -4 
and -5 mm (n=5/mouse) were stained and imaged (10x) using a Nikon Eclipse 90i microscope 
(Nikon Instruments Europe, Amsterdam, The Netherlands). We quantified GFAP staining and the 
number of dense, sparse and total amyloid plaques, intraneuronal Aβ-positive neurons and 
phosphorylated tau-positive neurons in regions/fields (680 x 840 μm) in distinct individual sections 
(≥ 4) of 3xTg-AD Veh (n=6) and 3xTg-AD Se (n=7) mice using the Cell Counter plugging of 
ImageJ.  
 
Statistical analysis 
Behavioral comparisons were conducted with one-way analysis of variance (ANOVA) followed by 
Bonferroni post-hoc test. Morris water maze results were analyzed with two-way ANOVA for 
repeated measures (RM), followed by Bonferroni post-hoc test by using SigmaStat software (Systat 
Software, San Jose, CA). Statistical analyses of pathological and biochemical studies were performed 
using t-test (immunohistochemistry) or two-way ANOVA followed by Bonferroni post-hoc test for 
multiple comparisons (biochemical studies) by using Prism software (GraphPad, La Jolla, CA). *P < 
0.05, **P < 0.01, ***P < 0.0001. 
 
Ethical experimental statement 
This study was performed in accordance with the experimental European Union guidelines and 
regulations (2010/63/EU). Experimental protocols and experiments involving vertebrate animals 
were conducted in accordance with the ethical protocol approved by the Animal and Human Ethical 
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Committees of the Katholieke Universiteit Leuven and Universitat Autònoma de Barcelona (protocol 
number: CEEAH 2896) and the local Governmental Ethical Committee Generalitat de Catalunya 
(protocol number: DMAH 8787). 
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Figure Legends 
Figure 1. Sodium selenate ameliorates idiopathic and anxiety behaviors in 3xTg-AD mice 
A Ethological assessment of WT and 3xTg-AD mice after chronic vehicle (Veh) or sodium selenate 
(Se) treatment. Loco: locomotion; seat: rearing seated; wall: rearing against the wall; free: rearing 
free; sift: sifting; groom: grooming; chew: chewing; still: stillness.  
B Evaluation of mice in the corner index task. Counts: number of visited corners or rearings.  
C, D Assessment of neophobia/anxiety in the dark-light test. 3xTg-AD mice show significantly 
increased latencies (C) and reduced transitions (D) towards the light compartment, a behavior 
reversed by Se treatment.  
E Evaluation of fear associative memory in the passive avoidance test. The reduced latencies to enter 
to the dark compartment were reversed in 3xTg-AD mice after Se treatment.  
F, G Assessment of well-being and social collaboration in the nest building test. 3xTg-AD mice 
showed a significant less nest-building ability than WT groups, while Se treatment increases nesting 
activity in 3xTg-AD mice (F) as observed in representative pictures of nests (G).  
Data represent mean ± s.e.m. Number of mice: WT vehicle (n=11), WT Se (n=10), 3xTg-AD vehicle 
(n=9) and 3xTg-AD Se (n=15). Statistical analysis was determined by one-way ANOVA followed by 
Bonferroni post hoc test. * P < 0.05, ** P < 0.001, *** P < 0.001. 
Figure 2. Selenium treatment reverses spatial learning and memory deficits in 3xTg-AD mice 
A Spatial learning curves in the Morris water maze. The spatial training consisted of five-day 
training in the hidden platform version of the task. The performance of all groups improved 
significantly during the training days, although 3xTg-AD Veh mice show significantly longer 
latencies than the rest of groups.  
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B Spatial reference memory in the MWM after treatment. Results represent the time spent in each 
quadrant in the post training probe trial. Compared to WT groups, 3xTg-AD Veh mice did not show 
a preference for the target quadrant (SE), whereas Se treatment enhances target quadrant preference 
in 3xTg-AD mice.  
C Swimming pathlengths during navigation in the probe trial.  Heat plots of pathlengths of 
representative experimental mice during the probe trial.  
D Spatial navigation strategies of mice in the MWM. Top: Schematic representations of non-spatial 
and spatial navigation strategies in the MWM. Bottom: Effect of sodium selenate on non-spatial and 
spatial learning strategies in the MWM. Data represent mean ± s.e.m. Number of mice: WT vehicle 
(n=11), WT Se (n=10), 3xTg-AD Veh (n=9) and 3xTg-AD Se (n=14). Statistical analysis was 
determined by two-way ANOVA followed by Bonferroni post hoc test. * P < 0.05, *** P < 0.0001 
Figure 3. Amyloid pathology is not affected by selenium treatment in 3xTg-AD mice   
A Cerebral amyloid pathology in 3xTg-AD mice at 13-14 months of age. Coronal brain sections of 
vehicle- (Veh) and Se-treated 3xTg-AD mice were stained with an Aβ antibody (6E10) to reveal the 
presence of intraneuronal Aβ (middle image) and amyloid plaques (right image) in the hippocampus. 
The middle and right images are magnified images of the left dashed areas (insets) corresponding to 
CA1 and subiculum subregions. Scale bars = 40 µm and 250 µm.  
B Quantification of amyloid pathology in the treated groups. Results include number of dense, sparse 
or total Aβ plaques and intraneuronal Aβ-positive neurons per section, for brain regions shown in A. 
Data represent mean number ± s.e.m. n=4-5 sections/mouse; n= 6-7 mice/group.  
Figure 4. Tau pathology is reduced by selenium treatment in 3xTg-AD mice   
A Cerebral tau pathology is present in the brain of 3xTg-AD at 13-14 months of age. Images show 
coronal brain sections of WT control (left) and vehicle- (middle) or Se (right)-treated 3xTg-AD mice 
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stained with antibodies against phosphorylated tau (CP13: Ser202; PHF1: Ser396/Thr404) and 
conformational aggregated tau (MC1) found in AD. Upper three rows correspond to CA1 
hippocampus and the bottom row images correspond to the temporal cortex. Scale bar = 50 µm. 
Right: quantitative imaging analysis of phosphorylated or aggregated tau-positive neurons in vehicle- 
and Se-treated 3xTg-AD mice. Data represent number of tau-positive neurons per selected region ± 
s.e.m. n=4-5 sections/mouse; n= 6-7 mice/group.  
B,C Biochemical analysis of tau and GSK3β in the hippocampus of WT and 3xTg-AD mice. 
Western blot images (B) and quantitative analysis (C) of phosphorylated tau (CP13, AT180 and 
PHF1), total tau (TG5 and 17025) and total and phosphorylated (Ser9) GSK3β. Original 
immunobloting scans and parts of the blots used for the figures are shown in Supplemental 
Information. Data represent relative levels of total and phosphorylated proteins as fold change ± 
s.e.m. n=4-5 mice/group. Statistical analysis was determined by t-test (A) or two-way ANOVA 
followed by Bonferroni post hoc test (C).  *P < 0.05, ** P < 0.001 compared to 3xTg-AD Veh 
group. 
Figure 5. Chronic selenium treatment reduces astrocytosis in the hippocampus of 3xTg-AD 
mice   
A Immunohistological analysis of astrocytes in 3xTg-AD mice. Coronal brain sections stained with 
GFAP antibody to detect reactive astrocytes in the hippocampus of 14 month-old 3xTg-AD mice 
treated with vehicle (Veh) or Se for four months. Images show reduced GFAP staining in the CA1, 
CA3 and DG regions but not in the corpus callosum (CC) of 3xTg-AD mice treated chronically with 
Se (bottom) compared with vehicle (top). Scale bar = 50 µm. Data represent percentage of area 
stained with GFAP ± s.e.m. n=4-5 mice/group. Statistical analysis was determined by t-test  *P < 
0.05 compared to 3xTg-AD Veh group.  
 26
B Biochemical analysis of GFAP in the hippocampus of treated mice. Western blot images and 
quantification of GFAP levels in the hippocampus of WT and 3x-Tg-AD mice. Se reduces GFAP 
levels in the hippocampus of 3xTg-AD mice. Original immunobloting scans and parts of the blots 
used for the figures are shown in Supplemental Information. Data represent fold relative levels of 
GFAP ± s.e.m. n=4-6 mice/group. Statistical analysis was determined by two-way ANOVA followed 
by Bonferroni post hoc test. ** P < 0.001 
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Table 1. Quantitative analysis of tau pathology in the brain of 3xTg-AD mice after vehicle and selenium 
treatment 
 
 
Data indicate the number of phosphorylated (CP13: Ser 202; PHF1: Ser 396/404) or aggregated (MC1) tau-
positive neurons/field of different brain sections (n=4-5) per mouse (n=6-7 mice/group). Abbreviations: 
CA1, CA2, CA3: Hippocampal Cornu Ammonis 1/2/3 regions,  DG: dentate gyrus, PCx: Parietal cortex; 
ACx: Auditory cortex, ECx: Entorhinal cortex, BLA: Basolateral amygdala. ND: not determined. ▲ 
Temporal auditory cortex. * P < 0.05 vs Vehicle 
 
 
 
 CP13 (pSer202) PHF1 (pSer396/404) MC1 (Tau conf.) 
       
Brain 
Region 
Veh Se Veh Se Veh Se 
       
       
CA1 97.7 ± 17.9 72.3 ± 13.1 97.8 ± 9.1 85.2 ± 10.3 45.9 ± 3.3 26 ± 6.6 * 
CA2 68.7 ± 10.4 49 ± 10.3 87.4 ± 20.5 68 ± 16 16.5 ± 7.1 10.5 ± 3.2 
CA3 70 ± 14.8 70.8 ± 15.3 79.3 ± 20.5 94.8 ± 26.4 5.5 ± 1.7 5.8 ± 2.1 
DG 44.6 ± 8.8 49.9 ± 8.7 43.2 ± 8.1 58.4 ± 13.3 1.8 ± 0.7 1.1 ± 0.3 
PCx 124.4 ± 22.9 127.6 ± 16.7 310.1 ± 42.5 297.5 ± 38 0.3 ± 0.1 0.5 ± 0.3 
ACx 159.4 ± 15 143.8 ± 15.5 274.1 ± 21 231.8 ± 24.6 3.1 ± 1 0.9 ± 0.3 *▲ 
ECx 152.1 ± 16.3 133.8 ± 24.5 205.9 ± 25.8 224 ± 72.5 ND ND 
BLA 135.8 ± 11.4 110.3 ± 26.9 214.5 ± 16.2 200 ± 23 14.3 ± 2 11.3± 3.7 





